Status:
COMPLETED
Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis
Lead Sponsor:
Casa Espirita Terra de Ismael
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Atopic Dermatitis
Effects of Immunotherapy
Eligibility:
All Genders
3+ years
Phase:
PHASE4
Brief Summary
Atopic dermatitis (AD) is a chronic and recurrent inflammatory disease, prevalent between 1 and 20% in the world population, with a predominance of childhood, but which may be present in adult life. A...
Detailed Description
A total of 94 patients, 3 years of age or older, with clinical diagnosis of AD, without distinction of gender, ethnicity or social group, will be selected at HCFMRP-USP Allergy and Dermatology outpati...
Eligibility Criteria
Inclusion
- Diagnosis of AD according to Hanifin and Rajka criteria;
- Age greater than or equal to 3 years;
- SCORAD equal to or greater than 15 points;
- Presence of skin tests and / or specific IgE positive for Dermatophagoides pteronyssinus and / or Dermatophagoides farinae;
Exclusion
- Pregnancy or breastfeeding;
Key Trial Info
Start Date :
May 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 26 2020
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT03388866
Start Date
May 2 2018
End Date
June 26 2020
Last Update
August 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
Ribeirão Preto, São Paulo, Brazil, 14048-900